T 0226/98 (Famotidine/RICHTER GEDEON) du 07.02.2001
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2001:T022698.20010207
- Date de la décision
- 7 février 2001
- Numéro de l'affaire
- T 0226/98
- Requête en révision de
- -
- Numéro de la demande
- 87306882.9
- Classe de la CIB
- C07D 277/48
- Langue de la procédure
- Anglais
- Distribution
- Publiées au Journal officiel de l'OEB (A)
- Téléchargement
- Décision en anglais
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- Morphologically homogenous forms of famotidine and processes for their preparation
- Nom du demandeur
- RICHTER GEDEON VEGYESZETI GYARR.T.
- Nom de l'opposant
- Yamanouchi Pharmaceutical Co.
Ltd - Chambre
- 3.3.01
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 123(2) 1973European Patent Convention Art 123(3) 1973European Patent Convention Art 54(1) 1973European Patent Convention Art 54(2) 1973European Patent Convention Art 84 1973European Patent Convention R 57a 1973
- Mots-clés
- Main request: clarity (no) - obscurity of delimiting feature
- Exergue
- 1. In a claim related to a product as such (here: famotidine form "B"), the feature "as a pharmaceutical product" for defining a pharmaceutical standard of purity renders said claim unclear in the absence of a generally accepted quantitative definition for the purported standard of purity. Nor can this expression be considered to be a commonly accepted functional feature as no clear definition can be derived therefrom (see point 7.2 of the reasons).
2. As purity standards are likely to change with time for a number of reasons (e.g. new manufacturing process, new or improved analytical tools, change of criteria for obtaining a marketing authorization), it remains obscure what is considered to be the required product quality when defined by the feature "as a pharmaceutical product" (see point 7.3 of the reasons).
ORDER
For these reasons it is decided that:
The appeal is dismissed.